EIR Biopharma IPO
EIR Biopharma, Inc. · San Francisco, CAwww.eirbiopharma.com
Price range
$4.00 – $5.00
3.75M shares offered
Withdrawn
Nov 16, 2026
2 days ago
Deal size
$16.9M
At range midpoint
Early-stage biotech developing licensed drug candidates for dry age-related macular degeneration and optic nerve damage such as glaucoma.|Read more
Key takeaways
Summarised with AI from the S-1 filed Feb 17, 2026. Check the prospectus before relying on it.
- 1EIR has no revenue and reported a net loss of $435,505 for the nine months ended September 30, 2025.
- 2At September 30, 2025, EIR had $179,932 in cash, total liabilities of $2.17 million and a stockholders' deficit of $1.93 million.
- 3EIR planned to sell 3,750,000 shares at $4.00–$5.00 each, for estimated net proceeds of about $14.9 million at the $4.50 midpoint.
- 4Before the offering, the two executives together beneficially owned 63.5% of the shares, and EIR expected to make additional stock grants to their consulting firms in connection with the offering.
- 5Both drug candidates are preclinical, and EIR plans to start human studies in early 2027 for EIR-1003 and late 2027 for EIR-0205.
Existing investors may buy: current holders indicated interest in the IPO (not binding)
Emerging growth company · Smaller reporting company
Offering terms
Common Stock, par value $0.00001 per share on the New York Stock Exchange
- Price range
- $4.00 – $5.00
- Shares offered
- 3.75M
- Over-allotment
- 563K
- Deal size
- $16.9M
- Net proceeds (est.)
- $14.9M
- Underwriting discount
- 8.0%
- Lock-up
- 181 days
- Registered maximum
- $21.6M
- Who is locked up
- The company, directors, executive officers and holders of 5% or more. Kingswood Capital Partners may release shares at any time at its discretion.
- Dividends
- EIR has never paid cash dividends and does not plan to pay any in the foreseeable future.
About EIR Biopharma
EIR Biopharma is an early-stage drug developer that works on treatments for eye disease. It licenses preclinical drug candidates from research universities and plans to move them into human trials. It has worldwide exclusive licenses from Weill Cornell Medical College of Cornell University and from the University of Miami. Both universities also own shares in the company.
EIR has two lead candidates. EIR-0205 is meant to treat the dry form of age-related macular degeneration, and human studies are planned for late 2027. EIR-1003 is meant to help optic nerves regenerate in conditions such as glaucoma, and human studies are planned for early 2027. Neither candidate has been tested in people yet.
EIR runs as a semi-virtual company. It has no full-time employees and two part-time executive officers, and it relies on outside contract research and manufacturing firms. It has no revenue. At September 30, 2025, it had $179,932 in cash and a stockholders' deficit of $1.93 million.
- Stage
- Preclinical-stage biotech, pre-revenue
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Francisco, California
- CEO
- Anthony Cataldo
- Employees
- 0
- Founded
- 2022
- Incorporated in
- DE
- Fiscal year end
- Dec 31
- SEC CIK
- 1966774
Products & pipeline
EIR licenses early-stage eye disease drug candidates from universities and pays for their development through clinical trials, with the goal of winning regulatory approval. It would owe royalties and milestone payments to the licensing universities. It has no revenue today.
| Program | Stage | Details |
|---|---|---|
| EIR-0205 | Preclinical | A small-molecule cyclodextrin licensed from Cornell, designed to clear lipofuscin waste from the retina to treat dry age-related macular degeneration.Next: Human clinical studies planned for late 2027 |
| EIR-1003 | Preclinical | A peptide-like drug licensed from the University of Miami that mimics ephrin ligands to promote optic nerve regeneration, for conditions such as glaucoma.Next: Human clinical studies planned for early 2027 |
Market opportunity
Research to Prevent Blindness projects that vision loss, eye diseases and vision disorders will carry an estimated $276 billion annual economic burden in the US in 2025, and NAEVR estimates this will reach nearly $373 billion by 2050. There is no FDA-approved treatment for dry AMD, which accounts for about 80% of AMD patients.
Strengths, as the company sees them
- Worldwide exclusive licenses from Cornell University and the University of Miami
- Founders with more than 50 years of combined senior biotech and pharma management experience
- Semi-virtual model intended to keep overhead costs low
- Candidates have shown activity in animal models of eye disease
Strategy
- License preclinical eye disease assets that can reach the clinic within 14–18 months
- Fund sponsored research at partner institutions in exchange for options on new candidates
- Advance EIR-1003 through IND-enabling studies and Phase 1/1B trials
- Use contract research and manufacturing organizations for studies and drug supply
- Run Phase I studies at the University of Miami's Bascom Eye Institute
Financials (USD)
EIR has no revenue, small ongoing losses, very little cash and liabilities larger than its assets.
| Period | 9M 2025 | 9M 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Gross profit | $0 | $0 |
| Net income (loss) | −$436K | −$1.1M |
| Operating cash flow | −$214K | −$624K |
Balance sheet, Sep 30, 2025
- Cash & investments
- $180K
- Total assets
- $239K
- Total liabilities
- $2.2M
- Stockholders' equity
- −$1.9M
Key metrics
- Operating expenses
- $244,0439M 2025
- Interest expense
- $191,4629M 2025
- Working capital
- -$1,934,173As of 2025-09-30
- Accumulated deficit
- -$4,564,260As of 2025-09-30
- Convertible notes outstanding (principal)
- $1,831,250As of 2025-12-31
Use of proceeds
Most of the stated uses go to moving EIR-1003 through IND approval and early clinical trials. The rest would go to other research, manufacturing and general corporate needs.
- Net proceeds to the company
- $14.9MAt the $4.50 midpoint, no over-allotment
- Cash expected to last
- At least twelve months after offeringWith existing cash
- 1Preclinical development of EIR-1003 through IND approval$2.0M
- 2Clinical development of EIR-1003 through Phase 1/1B trials$5.0M
- 3Other R&D, manufacturing capacity, working capital and general corporate purposes
Ownership & dilution
- Shares before IPO
- 27.92M
- Shares after IPO
- 31.33M
- Dilution to new buyers
- $4.08/share
- Book value per share after
- $0.42vs $4.50 paid
- Selling stockholders
- Yes
Indication of interest: Certain existing stockholders indicated interest in buying shares in the offering; the amount was left blank in the filing.
The 30,000 Series A preferred shares convert into 1,500,000 common shares, and the OID convertible notes convert into 406,944 shares at the $4.50 midpoint, when the offering closes.
| Principal holders | Before | After |
|---|---|---|
| Martin Schroeder (via Emmes Group Consulting) · Insider | 40% | — |
| Anthony J. Cataldo · Insider | 23% | — |
| Ines Garcia · Investor | 13% | — |
| Justin Keener · Investor | 10% | — |
| Bigger Capital Fund, LP · Investor | 5.0% | — |
| Cornell University | 4.1% | — |
| University of Miami | 4.0% | — |
Management & board
| Name | Background |
|---|---|
| Executive officers | |
| Anthony Cataldo, 75Chief Executive Officer and Chairman | Former CEO of GT Biopharma; former Chairman and CEO of Genesis Biopharma (now Iovance Biotherapeutics) |
| Martin Schroeder, 72President, CFO, Chief Science Officer, Treasurer, Secretary and Director | EVP and Managing Director of Emmes Group since 1998; former Chief Scientific Officer of GT Biopharma |
Funding before the IPO
Private rounds and loans disclosed in the registration statement.
| Date | Round | Amount | Price/share |
|---|---|---|---|
| Apr 2022 | Founder sharesFounders | $5K | — |
| Nov 2022 | Series A preferred (with warrants)Two accredited investors | $750K | $25 |
| Dec 2022 | License sharesUniversity of Miami | — | — |
| Jan 2023 | License sharesCornell University | — | — |
| Dec 2023 | Convertible notes (OID), through May 2024 | $908K | — |
| Jun 2025 | Convertible note (OID)Mark Bianchi Inc. | $200K | — |
| Sep 2025 | Convertible note (OID)Lamat Ventures Ltd. | $100K | — |
Key risks
The most important of the risk factors the company lists. The prospectus has the full list.
- 1Very limited cash and ongoing losses
EIR had $179,932 in cash and a stockholders' deficit of $1.93 million at September 30, 2025. It expects losses to continue and may never become profitable.
- 2Entirely preclinical pipeline
Neither drug candidate has been tested in people. Animal results may not carry over to humans, and approval could take many years or never come.
- 3Dependence on university licenses
EIR's assets are licensed from Cornell and the University of Miami. The licenses require development milestones, royalties and milestone payments of up to about $4.4 million (Miami) and $4.55 million plus $5 million (Cornell).
- 4Thin management and governance
EIR has two part-time executives, no full-time employees and no independent directors yet. The CEO filed for personal bankruptcy in 2023, and the case was dismissed.
- 5Concentrated insider control
The two executives beneficially owned 63.5% of the shares before the offering. EIR also expects to give each of their consulting firms a stock grant equal to 10% of fully diluted shares in connection with the offering.
- 6Additional dilution
Warrants for 3,000,000 shares at $0.60, options for 2,750,000 shares at $0.85, and the planned consulting stock grants could further dilute new investors.
- 7Reliance on third parties
EIR depends on contract research and manufacturing firms to run its studies and make its drug supply.
Underwriters & advisers
- Underwriters
- Kingswood Capital Partners, LLC
- Auditor
- Salberg & Company, P.A.
- Company counsel
- Wilson Sonsini Goodrich & Rosati, Professional Corporation
- Transfer agent
- West Coast Stock Transfer, Inc
- Over-allotment window
- 45 days
Prospectus & SEC filings
The registration statement, its amendments and the final prospectus, straight from SEC EDGAR.
| Date | Form | Document | Open |
|---|---|---|---|
| Nov 16, 2026 | RW | Withdrawal request (RW) | |
| Feb 17, 2026 | S-1 | Registration statement (S-1) · 9 documents |
EIR Biopharma IPO: frequently asked questions
More IPOs
Upcoming and recently priced deals.
Source: EIR Biopharma, Inc.'s filings on SEC EDGAR. Dates marked approximate are derived from filing dates. Summaries are AI-assisted; the prospectus is the authority. This page is for information only and is not investment advice.